Kalaris Reports Third Quarter 2025 Financial Results and Provides Business Updates
Kalaris Therapeutics (NASDAQ:KLRS) is now covered by analysts at Citizens Jmp. They set a "mkt outperform" rating and a $20.00 price target on the stock.
Kalaris Expands Leadership Team Appointing Matthew Gall, MBA, as Chief Financial Officer
Kalaris Therapeutics (NASDAQ:KLRS) is now covered by analysts at Citigroup Inc.. They set an "outperform" rating on the stock.
Kalaris to Present at Stifel 2025 Annual Healthcare Conference